
Afuresertib hydrochloride
CAS No. 1047645-82-8
Afuresertib hydrochloride( GSK 2110183 hydrochloride | GSK2110183 hydrochloride )
Catalog No. M10235 CAS No. 1047645-82-8
A potent, selective, ATP-competitive pan-AKT inhibitor with biochemical IC50 of 0.08/2/2.6 nM for AKT1/2/3.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 40 | Get Quote |
![]() ![]() |
5MG | 61 | Get Quote |
![]() ![]() |
10MG | 86 | Get Quote |
![]() ![]() |
25MG | 149 | Get Quote |
![]() ![]() |
50MG | 239 | Get Quote |
![]() ![]() |
100MG | 414 | Get Quote |
![]() ![]() |
200MG | 538 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAfuresertib hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, ATP-competitive pan-AKT inhibitor with biochemical IC50 of 0.08/2/2.6 nM for AKT1/2/3.
-
DescriptionA potent, selective, ATP-competitive pan-AKT inhibitor with biochemical IC50 of 0.08/2/2.6 nM for AKT1/2/3; also inhibits PKA (IC50=1.3 nM) and AKT1 E17K mutant (IC50=0.2 nM), selective over PKC, PKG isoforms and p70S6K; orally bioactive.Gastric Cancer Phase 1 Discontinued(In Vitro):Afuresertib (GSK 2110183) exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G1 phase.Western blotting analysis shows that Afuresertib increases the expression of p21WAF1/CIP1 and decreases the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated with fibroblast core serum response. (In Vivo):Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.
-
In VitroAfuresertib (GSK 2110183) exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G1 phase. Western blotting analysis shows that Afuresertib increases the expression of p21WAF1/CIP1 and decreases the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated with fibroblast core serum response.
-
In VivoMice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.
-
SynonymsGSK 2110183 hydrochloride | GSK2110183 hydrochloride
-
PathwayPI3K/Akt/mTOR signaling
-
TargetAkt
-
RecptorAkt
-
Research AreaCancer
-
IndicationGastric Cancer
Chemical Information
-
CAS Number1047645-82-8
-
Formula Weight463.7841
-
Molecular FormulaC18H18Cl3FN4OS
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 52 mg/mL
-
SMILESCN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl.Cl
-
Chemical Name2-Thiophenecarboxamide, N-[(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dumble M, et al. PLoS One. 2014 Jun 30;9(6):e100880.
2. Spencer A, et al. Blood. 2014 Oct 2;124(14):2190-5.
3. Arceci RJ, et al. Pediatr Blood Cancer. 2017 May;64(5).
molnova catalog



related products
-
Methyl hesperidin
Methyl Hesperidin is a flavanone glycoside (flavonoid) (C28H34O15) found abundantly in citrus fruits.
-
GSK-690693
A potent, ATP competitive, pan-AKT inhibitor with IC50 of 2, 13, and 9 nM against AKT1, 2, and 3, respectively.
-
Lupeol
Lupeol is a pentacyclic triterpene that has anti-inflammatory and antioxidant activity.